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Mouse mammary tumour virus (MMTV) causes breast cancer in mice, and MMTV-specific antibodies develop to high titers among
mice infected as adults. Whether MMTV or a related virus infects humans is uncertain, because MMTV DNA sequences have been
detected inconsistently and because serologic methods have varied widely. The current study used immunoblot and
immunoprecipitation with four strains of MMTV (RIII, FM, C3H, and LA) to detect specific antibodies in 92 sera from US women
with breast cancer and in masked dilutions of monoclonal hybridoma and hyperimmunised goat positive-control reagents. In these
positive controls, MMTV antibodies of the expected molecular weights were detected at high titer (1:100 in the monoclonal reagent,
1:10000 in the hyperimmunised goat serum). Nearly 30% of the sera from women with breast cancer had at least one faint band on
an immunoblot, but none of these matched the molecular weight of bands revealed by probing the same blot strips with the goat
serum. The goat serum readily immunoprecipitated MMTV antigens from all four strains of MMTV, but MMTV antigens were not
immunoprecipitated by any of the six breast cancer sera that had four or more nonspecific immunoblot bands. Thus, among women
with breast cancer, we found no MMTV-specific antibodies. The upper 95% confidence limit implies that MMTV seroprevalence
among breast cancer patients does not exceed 3%.
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The mouse mammary tumour virus (MMTV), a betaretrovirus,
causes breast cancer in mice. During the past 10 years, molecular
evidence of MMTV in human breast cancer tissue has been
reported by a few laboratories using polymerase chain reaction
(PCR) techniques (summarised in Holland and Pogo (2004)).
These findings are controversial, because other laboratories have
been unable to replicate detection of MMTV and because the DNA
amplified by PCR in some laboratories has had homology with
nonviral sequences in the human genome (summarised in Mant
et al (2004)). Serologic studies to identify MMTV antibodies
complement these PCR-based molecular studies of breast cancer
tissue. During the late 1970s and early 1980s, detection of serum
antibodies against MMTV-infected cells or proteins from these
cells among women with breast cancer provided support for the
possibility of a human homologue of MMTV. There was, however,
substantial heterogeneity in methods, in antigens recognised by
the sera, and in seroprevalence associations. The results and
limitations, particularly with respect to specificity, of these early
studies were reviewed by Dion et al (1987). By Western
immunoblot with disrupted, purified milk-borne MMTV of the
RIII strain, Dion and co-workers found no antibodies against
MMTV viral antigens in 1:5 dilutions of sera from 30 breast cancer
patients or 30 control patients (Dion et al, 1987). In 1:8 dilutions
of sera in enzyme immunoassays, Dion et al found modestly
higher reactivity against column-purified p18 from MMTV but not
against four other MMTV column-purified proteins or glyco-
proteins in breast cancer patients compared to controls (Dion et al,
1987). Among 300 Czech subjects (90 healthy controls, 60 with
breast cancer, and 150 with other malignancies or serious diseases)
whose sera, diluted 1:100, were tested by immunoblot heavily
loaded with proteins and glycoproteins from the GR/N strain of
MMTV, Kovarik et al found frequent reactivity against a 42kDa
cellular contaminant of the virus, but few with reactivity against
viral antigens and no differences between cases and controls
(Kovarik et al, 1989). All of the previously published studies used
only a single strain of MMTV. We, therefore, sought to estimate
the MMTV seroprevalence among US women with breast cancer by
using a wider variety of MMTV strains. We used both
immunoblotting and immunoprecipitation to maximise specificity
of the anti-MMTV reactivity.
MATERIALS AND METHODS
Patients and controls
Between 1979 and 1988, the Immunodiagnosis Serum Bank
collected, separated, and stored frozen sera from patients at the
Mayo Clinic who had common malignancies (Dimagno et al,
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s1989). To estimate MMTV seroprevalence, sera from 92 women
with breast cancer in this bank were selected, based on total
number of available aliquots and availability of at least one 0.25ml
aliquot. Data on age at blood draw, histologic diagnosis, tumour
stage, cancer treatment history, and smoking status were available.
Identifying data had been removed. Exemption from Institutional
Review Board review was obtained from the NIH Office of Human
Subjects Research. Monoclonal a-gp52 hybridoma supernatant BL6
5D, as well as caprine sera from goats hyperimmunised with
MMTV (a-MMTV) or with gp52 (polyclonal a-gp52), served as
positive control reagents (Dzuris et al, 1999; Purdy et al, 2003). In
a central repository, three aliquots of each of these reagents (neat,
1:10 and 1:100 dilutions in defibrinated plasma (Basematrix, BBI-
Biotech Inc., Frederick, MD, USA)) were put into vials identical to
the human sera. The nine positive controls were interspersed
among the 92 human sera and could not be identified by the
laboratory. To assess the integrity of the sera, they were tested for
rubella antibodies with a commercial agglutination test (BD
Biosciences Inc.).
Detection of MMTV-specific antibodies
Immunoblot analysis was performed as described previously
(Selmi et al, 2004). Briefly, total protein was extracted from
virions purified by pelleting through sucrose cushions, as
previously described (Le Bon et al, 1999). The virions were
purified from mammary tumours of C3H/HeN mice infected with
MMTV (FM) or MMTV (LA), milk from RIII mice (MMTV (RIII);
a gift from Akhil Vaidya), or supernatants from the cultured
mammary tumour cell line Mm5MT (MMTV (C3H)). Virions were
disrupted in lysis buffer containing 25mM Tris-HCl (pH 8.0),
150mM NaCl, 2mM EDTA, 0.1% sodium dodecyl sulfate, 0.5%
Nonidet P-40, and 0.5% deoxycholate. The proteins were separated
by sodium dodecyl sulfate–10% polyacrylamide gel electro-
phoresis (SDS–PAGE) and transferred to nitrocellulose. As the
virus preparations varied in purity, we normalised the amounts of
virus electrophoresed in each lane by initially running different
dilutions of the virus preparations and probing the filters with goat
anti-MMTV serum, as described below.
Sera were kept frozen at or below 701C until testing. Each
masked serum specimen was diluted 1:100 in phosphate-buffered
saline (PBS) containing 0.1% Tween-20 (PBS-Tween) and 5%
nonfat dried milk, incubated for 5h with the blots and then washed
extensively with PBS-Tween. As the primary sera were masked, we
used a mixture of horseradish peroxidase (HRP)-conjugated
donkey anti-human (1:8000; Jackson Immunoresearch Inc., West
Grove, PA), rabbit anti-goat (1:5000; Sigma Inc., St. Louis, MO)
and sheep anti-mouse (1:5000; Amersham Inc., Piscataway, NJ)
secondary antibodies to detect bound primary antibodies. This
mixture was added to each blot in PBS-Tween-milk, incubated for
30min and again washed extensively with PBS-Tween. To ensure
that the mixture of secondary antibodies was species-specific, we
also blindly tested 22 of the samples with the anti-human
secondary antibody alone and found that the same pattern of
bands seen with the mixture, except for two samples that were
masked, diluted goat serum. These latter two samples showed no
bands on the virus blots probed with the human secondary
antibody alone but showed the typical MMTV pattern when the
mixture of secondary antibodies was used (not shown). The blots
were developed with ECL Enhanced Western Blotting Detection
Reagent, according to the manufacturer’s instructions (Amersham
Inc.) To characterise whether antibodies revealed in the immuno-
blots had similar molecular weight to those in caprine sera, blot
strips that demonstrated antibody bands were reprobed with
polyclonal goat anti-MMTV antisera (a-MMTV, 1:3000) followed
by the HRP-conjugated rabbit anti-goat secondary antibody.
Photographs of the blots with human and a-MMTV sera were
aligned and overlaid for visual comparison. Side-by-side compar-
isons are provided. To maximise detection, the human blots were
exposed for up to 5min.
For the immunoprecipitation experiment, approximately 50mg
of purified protein from each of the four MMTV strains in 200ml
final volume of RIPA buffer (25mM Tris, pH 7.8, 150mM NaCl,
2m M EDTA, 0.5% NP40, 0.5% deoxycholate, 0.1% sodium dodecyl
sulphate, 1mM PMSF, 5mgml
1 leupeptin, 5mgml
1 aprotinin,
2mgml
1 pepstatin A) were added to 1ml of human serum, or to
1ml of a 1:10 dilution of the polyclonal goat anti-MMTV serum
followed by 50ml of Protein G sepharose (Invitrogen Inc., Carlsbad,
CA) and incubated overnight at 41C. After extensive washing, the
proteins were eluted in 50ml of SDS–PAGE sample buffer and 10ml
were electrophoresed on SDS–polyacrylamide gels. The proteins
were then transferred to nitrocellulose. For the human sera,
Western blot analysis using polyclonal goat anti-MMTV and rabbit
anti-goat antibodies was carried out as described in the preceding
paragraph. For the control immunoprecipitation performed with
the goat anti-MMTV antisera, the Goat TrueBlot Western Blot Kit
(eBioscience Inc., San Diego, CA) was used for detection of the
viral proteins to prevent obscuring of MMTV bands by the goat
heavy and light chain immunoglobulin used in the immuno-
precipitation.
RESULTS
In 65 (71%) of the 92 sera from women with breast cancer, no band
was seen in any of the four MMTV immunoblots. One serum
demonstrated a smear pattern in three of the four MMTV
immunoblots and could not be evaluated. Of the other 26 sera,
across all four MMTV immunoblots, 14 (15%) had one band; two
(2%) had two bands; four (4%) had three bands; three (3%) had
four bands; two (#36 and 60) had six bands; and one (#16) had
eight bands (Table 1). Age, breast cancer histology, breast cancer
stage, history of cancer treatment, and smoking status did not
differ between women whose sera had multiple bands or one band
and those who sera had no band (data not presented).
There was heterogeneity in the frequencies of serologic
reactivity across the four MMTV strains. Considering all reactivity
of all sera (except the one with a smear pattern), there were 19
bands against MMTV strain RIII; 20 bands against strain FM; 18
bands against strain LA; and only five bands against strain C3H.
Serum #60 had two distinct bands of approximate molecular
weight 56 and 60kDa against each strain except C3H, and these
differed from the bands that were detected with the a-MMTV
positive control serum (Figure 1A). Serum #16 had one or more
bands against all four strains, all of which were very faint
compared with the a-MMTV positive control serum (Figure 1A).
None of the bands, including those in sera #60 and #16, had the
Table 1 Prevalence of antibody reactivity against four strains of MMTV
among women with breast cancer in the United States
Total bands
a No. (%) of women Median (range) age
More than 4 3 (3) 47 (37–53)
4 3 (3) 48 (41–61)
3 4 (4) 49 (40–58)
2 2 (2) 71 (55–86)
1 14 (15) 53 (35–71)
0 65 (71) 57 (33–95)
Smear 1 (1) 73
aSum of all discrete bands across the immunoblots of all four MMTV strains (RIII, FM,
C3H, and LA). As shown in Figure 1A, serum from Patient #16 had eight bands (1
against RIII, 2 against FM, 2 against C3H, and 3 against LA), and sera from Patients
#36 and 60 had six bands (two each of the same molecular weight against RIII, FM,
and LA).
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ssame molecular weight as the a-MMTV positive control serum on
the same blot strips (Figure 1A).
In contrast, the masked dilutions of the three positive control
reagents performed as expected. The caprine a-MMTV and
polyclonal a-gp52 reagents were detected at the final dilution,
1:10000; further dilutions were not tested. The monoclonal
hybridoma supernatant containing a-gp52 antibodies was detected
at 1:100 but not at 1:1000 or 1:10000. No antibody bands were
seen in an unmasked human negative control serum. Rubella
antibodies were detected in 85 (92%) of the 92 human sera. Rubella
antibodies were not detected in the three neat caprine and
monoclonal reagents, but they were detected in the reagents that
had been diluted with human plasma-derived Basematrix.
Immunoprecipitation assays were performed with the sera that
had four or more bands on immunoblots to determine whether the
reactivity was directed against MMTV proteins. As shown in
Figure 1B, these six sera (#4, 6, 16, 36, 60, and 84) had faint
background staining with prolonged exposure (20min), most
likely due to proteins present in the human sera, since they
occurred with virus partially purified from different sources (milk
(RIII), tumour tissue (FM and LA), and cultured cells (C3H)).
Importantly, the human sera did not immunoprecipitate MMTV-
specific antigens from any of the four strains. In contrast, MMTV
antigens were readily precipitated with the diluted goat a-MMTV
positive control serum (5s exposure). These data indicate that the
bands detected by the human serum samples were not MMTV viral
proteins.
DISCUSSION
We found that nearly 30% of sera from US women with breast
cancer had some serologic reactivity against protein in one or
more of four different MMTV strains. However, none of this
reactivity was specifically directed against MMTV antigens. This
reactivity could be due to contaminating cellular or milk proteins
present in the partially purified virion preparations. Alternatively,
the MMTV envelope, like all retroviruses, incorporates many
nonviral, cellular proteins as it is released from the cell. These
nonviral proteins can be immunogenic, as illustrated by the
protection of macaques against simian immunodeficiency virus
(SIV) by vaccination with cells that did not contain SIV (Stott,
1991). Given the similarities across mammalian species, it is not
surprising that some women would have developed antibodies
against one or more nonviral proteins in the preparations of
MMTV that we used. While it is possible that some of the women
with reactive sera were exposed to mice, it is more likely that the
antibodies we detected were cross-reactive with other cellular
antigens, possibly including auto-antibodies (Tax and Manson,
1987; Kovarik et al, 1989). Development of antibodies against
nonspecific autoantigens occurs frequently among women with
breast cancer (Coronella-Wood and Hersh, 2003).
Mice infected as adults that develop MMTV-induced mammary
cancers have life-long, high-titer antibodies against both MMTV
and heterophile antigens, (Bowen et al, 1976) whereas mice
infected as neonates generally have only a transient antibody
response (Luther et al, 1997; Purdy et al, 2003). Seronegative
MMTV infection of newborn humans resulting in breast cancer is
unlikely, because breast cancer risk is not increased among women
who were themselves breast-fed (Titus-Ernstoff et al, 1998). Thus,
if MMTV infects humans, antibodies should be detected. Unlike
sera from mice infected as adults, none of 91 sera from our women
with breast cancer had specific, much less high titer, antibodies
against MMTV. The upper 95% confidence limit for 0/91 implies
that MMTV seroprevalence among women with breast cancer does
not exceed 3%.
Antibodies should be present if genes that code for MMTV
envelope or other structural proteins are expressed in humans.
There are, however, no published reports of anti-MMTV
seropositivity among breast cancer patients in whom MMTV
RNA expression was found, nor among those in whom DNA
sequences resembling MMTV were found (Holland and Pogo,
2004). Likewise, there are no reports of MMTV DNA detection
among such patients who were putatively MMTV seropositive. One
laboratory, using PCR-based approaches, has reported detection of
MMTV-like DNA in liver biopsies and lymph nodes, as well as
84
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
C
3
H
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
IP
41 6 3 6 6 0 8 4
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
R
I
I
I
F
M
L
A
C
3
H
83 kDa
62 kDa
48 kDa
32 kDa
25 kDa
83 kDa
62 kDa
48 kDa
32 kDa
25 kDa
83 kDa
62 kDa
48 kDa
32 kDa
25 kDa
83 kDa
62 kDa
48 kDa
32 kDa
25 kDa
36 16 60
−MMTV
−MMTV −MMTV −MMTV −MMTV
6
A
B
Figure 1 MMTV antibody immunoblots and immunoprecipitation with human and goat sera. (A) (upper panel). Each human serum was tested by
western immunoblot for antibodies against antigens in four strains of MMTV (RIII, FM, C3H, and LA). Four sera (#60, 16, 36, and 84) demonstrating bands
are presented. Each blot was then stripped and re-probed with hyperimmunised goat antiserum (labeled a-MMTV). Although various bands are present with
each of these selected human sera (e.g., two bands against the RIII, FM, and LA strains in #36 and 60, four bands against the C3H strain in #84), none
matched the molecular weight of the bands revealed with the a-MMTV positive control serum. (B) (lower panel). Immunoprecipitation of antigens in four
strains of MMTV (RIII, FM, C3H, and LA) with six human sera and with hyperimmunised goat antiserum (a-MMTV). MMTV antigens precipitated only with
the a-MMTV positive control serum.
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sMMTV-like RNA in serum (Mason et al, 2004). Moreover, they
found anti-MMTV antibodies in seven of nine patients with
primary biliary cirrhosis (Mason et al, 2004). In that study, MMTV
antibodies were detected by immunoblot analysis of extracts made
from the Mm5MT cell line, the same cells from which we purified
the MMTV (C3H) virions, and they used the same polyclonal goat
a-MMTV antisera for a positive control. However, in a much larger
series of primary biliary cirrhosis patients, a different laboratory
was unable to detect MMTV-like DNA in either liver biopsies or
peripheral blood mononuclear cells by PCR or antibodies against
three different strains of MMTV, including the C3H strain (Selmi
et al, 2004). The human endogenous retrovirus (HERV) K10 has
substantial homology with MMTV, and specific antibodies can be
detected when HERV K10 envelope or core (gag) is expressed, as
occurs in some cases of testis cancer (Goedert et al, 1999). Mant
et al (2004) have suggested that the MMTV-like DNA sequences
detected in humans are not MMTV or HERV K10 but rather are
another homologous region of the human genome.
Our study has several weaknesses and strengths. The sera that
we evaluated were collected 15–20 years earlier, during which time
they might have deteriorated. However, storage of this collection at
or below 701C for up to 10 years was shown to have negligible
effect on serum chemistry values other than bilirubin and
creatinine (Dimagno et al, 1989). Moreover, some 15 years after
they were collected, sera from this collection were proven to
contain antibodies against human papilloma virus type 16 and
adeno-associated virus (Strickler et al, 1998; Strickler et al,
1999). More directly, in the current study, we found that 92% of
the sera that we tested had rubella antibodies, as expected for
women born before 1960. The sera were collected from one large
center in the US, were accompanied by limited clinical data,
and are not necessarily representative of all US women with
breast cancer. To strengthen our study, among the 92 sera from
women with breast cancer, we interspersed dilutions of masked
positive control sera. These controls demonstrated that our
methods could detect MMTV antibodies in masked goat sera
and a-gp52 monoclonal hybridoma supernatant. To maximise
sensitivity for detecting anti-MMTV in human sera, we used four
purified MMTV immunoblot preparations, as well as prolonged
exposure times. To maximise specificity of the anti-MMTV
reactivity, we used immunoprecipitation, as well as overlaying
immunoblots probed with caprine a-MMTV to directly compare
the number, strength, and molecular weights of immunoblot bands
found with human sera. In contrast to the a-MMTV positive
control serum, the human sera were negative or had only weak,
nonspecific reactivity.
In summary, we found no evidence of antibodies against MMTV
among US women with breast cancer.
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